Page last updated: 2024-08-24

imiquimod and decitabine

imiquimod has been researched along with decitabine in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Li, H; Li, X; Lin, N; Liu, L; Lu, Y; Luo, D; Sun, X; Wang, J; Yin, C; Zhang, M; Zhou, Y1

Other Studies

2 other study(ies) available for imiquimod and decitabine

ArticleYear
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Aberrant promoter methylation of Wnt inhibitory factor-1 gene is a potential target for treating psoriasis.
    Clinical immunology (Orlando, Fla.), 2023, Volume: 250

    Topics: Animals; Decitabine; Disease Models, Animal; DNA Methylation; Humans; Imiquimod; Keratinocytes; Mice; Mice, Inbred BALB C; Promoter Regions, Genetic; Psoriasis; Skin

2023